IV immunoglobulin and anti RH D when unresponsive to corticosteroids or

Iv immunoglobulin and anti rh d when unresponsive to

This preview shows page 10 - 12 out of 15 pages.

IV immunoglobulin and anti RH D when unresponsive to corticosteroids or spleenectomy or spleenectomy isn’t an option. Rituximab to lyse B cell and reduce immune recognition of platelets. Effectiveness of spleenectomy is based on 4 factors. Thrombopoietin receptor agonist to increase platelet production. Platelet transfusion may cause further antibody formation. Anti-fibrinolytic agent may be used for severe bleeding. Treatment Specific: Thrombotic thrombocytopenic purpura Plasmapheresis is used to aggressively reverse platelet consumption by supplying the 10
Image of page 10
appropriate vWf and enzyme and removing large vWf molecules that bind with platelets. Corticosteroids Spleenectomy Platelet transfusion generally is contraindicated because this may lead to new vWf platelet complex and increased clotting. Treatment Specific: Heparin Induced Thrombocytopenia Discontinue heparin and start direct thrombin inhibitor. Warfarin sould be started when platelet is at least 150,000. If clotting is severe, Plasmapheresis to clear the platelet aggregating igG from blood, protamine sulfate, thrombolytic agents, or surgery to remove clots. Platelet transfusion is NOT effective because it enhance thromboembolic events. Never give heparin or LMWH. Treatment Specific: Acquired thrombocytopenia from Decreased Platelet Production If the precipitating factor is unknown, the patient may receive corticosteroid. Platelet transfusion is given if life- threatening hemorrhage develops. Hemophilia: X-linked recessive disorder caused by defective coagulation factor 8 or 9. Hemophilia A Factor 8 deficiency, recessive, transmitted by female carriers, displayed almost exclusively in men. Most common hemophilia. Hemophilia B Factor 9 (Christmas disease) deficiency, recessive, transmitted by female, displayed almost exclusively in men Von Willebrand Disease Autosomal dominant, seen in both genders. (Recessive in severe form). Deficiency of von Willebrand coagulation protein. Factor 8 is bind with von Willebrand Most common congenital bleeding disorder. Treatment Prevent and treat bleeding Replacement therapy may be given before surgery and dental care. Desmopressin to stimulate an increase in factor 8 and VWF. This drug act on platelets and endothelial cells to cause the release of VWF which bind with factor8, thus increasing their concentration. IV/IN Anti-fibrinolytic therapy inhibits fibrin Lysis by inhibiting plasminogen activation in the fibrin clot, thereby enhancing clot stability. Complications Development of antibodies/inhibitor for factor 8 or 9. Transfusion complication. Thrombotic episode with use of factor 9.
Image of page 11
Image of page 12

You've reached the end of your free preview.

Want to read all 15 pages?

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture